Zbigniew Markowski - Helix BioPharma CEO and Pres
| HBP Stock | CAD 0.18 0.02 10.00% |
CEO
Dr. Zbigniew Markowski is Chief Executive Officer of the Company. Dr. Markowski comes with a diversified experience having had a career in business university and government. Among others from 2006 until January 10 2016 he served as Chairman of O.M. Finance Ltd a private investment and consulting company from 1998 to 2002 as vicechairman of Prokom Investments SA a Polish investment fund where he was responsible for the financial and pharmaceutical sectors and as Member of the Board of BIOTON SA a pharmaceutical company listed on the Warsaw Stock Exchange from 1993 to 2005 he was a leading coordinator for more than a dozen initial public offerings of Polish companies listed on the WSE. From 1995 he was member or Chairman of the Supervisory Board of many companies listed on the WSE and additionally he served as chairman of the Audit Committees of CIECH SA II NFI SA and ROBYG SA.In 1993 he served as Special Plenipotentiary to the Minister of Privatization and to the Minister of Foreign Trade and in 1994 he was appointed as Commercial Counselor of the Polish People Republic in Stockholm Sweden since 2016.
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 401 Bay Street, Toronto, ON, Canada, M5H 2Y4 |
| Phone | 905-841-2300 |
| Web | https://www.helixbiopharma.com |
Helix BioPharma Management Efficiency
The company has return on total asset (ROA) of (1.1188) % which means that it has lost $1.1188 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (12.0579) %, meaning that it generated substantial loss on money invested by shareholders. Helix BioPharma's management efficiency ratios could be used to measure how well Helix BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -6.68. In addition to that, Return On Capital Employed is likely to drop to 6.35. As of the 19th of April 2024, Asset Turnover is likely to grow to 0.53, while Total Assets are likely to drop about 879.8 K.Similar Executives
| Found 8 records | CEO Age | ||
| Kenneth Lalonde | Toronto Dominion Bank | N/A | |
| Timothy Hockey | Toronto Dominion Bank | 51 | |
| Michael Pedersen | Toronto Dominion Bank | N/A | |
| Bharat Masrani | Toronto Dominion Bank Pref | 67 | |
| Bharat Masrani | Toronto Dominion Bank | 67 | |
| Bharat Masrani | Toronto Dominion Bank Pref | 67 | |
| Gregory Braca | Toronto Dominion Bank | N/A | |
| Bharat Masrani | Toronto Dominion Bank Pref | 67 | |
Management Performance
| Return On Equity | -12.06 | ||||
| Return On Asset | -1.12 |
Helix BioPharma Corp Leadership Team
Elected by the shareholders, the Helix BioPharma's board of directors comprises two types of representatives: Helix BioPharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Helix. The board's role is to monitor Helix BioPharma's management team and ensure that shareholders' interests are well served. Helix BioPharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Helix BioPharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Albert Beraldo, Director | ||
| Artur Gabor, CEO Chairman | ||
| Steve Demas, COO | ||
| FCA FCA, CFO Secretary | ||
| Marek Orlowski, Independent Director | ||
| Slawomir Majewski, Independent Director | ||
| George Anders, Director | ||
| Heman Chao, Chief Scientific Officer | ||
| Theordore Witek, Director | ||
| Zbigniew Markowski, CEO and Pres | ||
| Sylwester Cacek, Director | ||
| Yvon Bastien, Independent Director | ||
| Gary Littlejohn, Director | ||
| Namrata Malhotra, Corporate Secretary | ||
| Jacek Antas, Chairman CEO | ||
| Sven Rohmann, Independent Director | ||
| Dr MA, Head RD | ||
| Srikanth Sola, Chief Officer | ||
| Christof Boehler, Chief Officer | ||
| MBA MBA, Chief Officer | ||
| Photios Michalargias, CFO | ||
| Patrick Frankham, COO |
Helix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Helix BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.06 | ||||
| Return On Asset | -1.12 | ||||
| Current Valuation | 36.28 M | ||||
| Shares Outstanding | 229.44 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Number Of Shares Shorted | 1.89 K | ||||
| Price To Earning | (7.09) X | ||||
| Price To Book | 68.24 X | ||||
| EBITDA | (5.98 M) | ||||
| Net Income | (6.29 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helix BioPharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Helix Stock analysis
When running Helix BioPharma's price analysis, check to measure Helix BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helix BioPharma is operating at the current time. Most of Helix BioPharma's value examination focuses on studying past and present price action to predict the probability of Helix BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helix BioPharma's price. Additionally, you may evaluate how the addition of Helix BioPharma to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |